Explore our collection of case studies, webinars, and publications to learn more about what we do and what it’s like to work with us. If you need additional information or have specific questions, please let us know .
Case Studies
Learn how leading labs have used our Virology products to advance assay development for SARS-CoV-2, dengue, and other viruses.
Learn how dengue and Zika RVPs enabled clinical progression of Takeda’s Zika and dengue vaccines
-0.jpg){kind=small}
Learn how SARS-CoV-2 RVPs enabled Immunome to test their antibody cocktail and progress their therapeutic into the clinic
.png){kind=logo}
SARS-CoV-2 RVPs and live virus show similar neutralization titers
.png){kind=small}
Learn how RVPs can be used for sera screening and immunogenicity assays
Webinars and Videos
Learn from the experts about characterizing viral vaccines and antibodies.
Featured Publications
Read peer-reviewed publications describing the applications of Reporter Virus Particles and other Integral Molecular products.
Flavivirus - Zika and DENV
Flavivirus - Zika and DENV
A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species Bohning et al. 2021 PLoS One 16, e0250516
Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus Baldwin et al. 2021 Nature Communications 12, 7320
Identification of the Seven Critical Residues that Control ZIKV-DENV Cross-reactivity to Engineer a Non-cross-reactive ZIKV Vaccine Grinyo-Escuer et al. 2025 Cell Reports 44, 116098
Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications Whitbeck et al. 2020 PLoS Neglected Tropical Diseases 14, e0008730
Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection Young et al. 2020 Scientific Reports 10, 3488
SARS-CoV-2
SARS-CoV-2
A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential Bird et al. 2024 Nature Communications 15, 274
A Phase I/II clinical trial of intradermal, controllable self-replicating ribonucleic acid vaccine EXG-5003 against SARS-CoV-2 Koseki et al. 2023 Vaccines 11, 1767
IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2 Nikitin et al. 2022 Science Immunology 7, eabl9943
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model Kalnin et al. 2022 Vaccine 40, 1289-1298
Filovirus - Ebola
Filovirus - Ebola
Convergence of a common solution for broad ebolavirus neutralization by glycan cap directed human antibodies Murin et al. 2021 Cell Reports 35, 108984